Adaptimmune : Phase 1 Trial Data On Liver Cancer Show Significant Antitumor Activity
5/9 17:23
(RTTNews) - Adaptimmune Therapeutics plc (ADAP) provided updated data from its Phase 1 ADP-A2AFP trial for patients with liver cancer. The data showed significant antitumor activity with the first-generation product targeting AFP that is encouraging for the potential of cell ther...